Biotech Values

[DewDiligence]

RARX—The deal still needs regulatory approval after several months of trying.

Still, there has been no disclosure from the company about interactions with the FTC since the 2/28/20 8-K posted in #msg-154416552.

The public info is enough to hold the price down.

If this were true, the share price would have tanked earlier, but it had been stable until the 9.5% drop yesterday—almost three weeks after the 8-K filing.